$207.51 3.3 1.6%
Last Trade - 9:10pm
| Market Cap | £21.55bn |
| Enterprise Value | £21.97bn |
| Revenue | £2.24bn |
| Position in Universe | 432nd / 6851 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,679 | 1,839 | 2,067 | 2,340 | 2,607 | 2,957 | 3,160 | 3,424 | +12.0% | ||
| +1.9 | +2.4 | +2.3 | +28.6 | -2.0 | +33.6 | +20.1 | +6.40 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 31, 1994 |
| Public Since | June 1, 1995 |
| No. of Shareholders: | 26 |
| No. of Employees: | 7,770 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 145,509,084 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 9001 Spectrum Center Blvd, SAN DIEGO, 92123-1438, United States |
| Web | https://www.resmed.com/ |
| Phone | +1 858 7462400 |
| Contact | () |
| Auditors | KPMG LLP |
As of 9:10pm, shares in Resmed Inc are trading at $207.51, giving the company a market capitalisation of £21.55bn. This share price information is delayed by 15 minutes.
Shares in Resmed Inc are currently trading at $207.51 and the price has moved by 27.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Resmed Inc price has moved by -13.47% over the past year.
Of the analysts with advisory recommendations for Resmed Inc, there are there are currently 2 "buy" , 4 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Resmed Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Resmed Inc is scheduled to issue upcoming financial results on the following dates:
The Resmed Inc dividend yield is 0.76% based on the trailing twelve month period.
Last year, Resmed Inc paid a total dividend of 1.56, and it currently has a trailing dividend yield of 0.76%. Looking ahead, Resmed Inc has not announced an ex-dividend date yet.
Resmed Inc has yet to annouce their ex-dividend date. The historic dividend yield on Resmed Inc shares is currently 0.76%.
To buy shares in Resmed Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Resmed Inc are currently trading at $207.51, giving the company a market capitalisation of £21.55bn.
Here are the trading details for Resmed Inc:
Based on an overall assessment of its quality, value and momentum, Resmed Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Resmed Inc are currently priced at $207.51. At that level they are trading at 6.27% discount to the analyst consensus target price of 0.00.
Analysts covering Resmed Inc currently have a consensus Earnings Per Share (EPS) forecast of 5.237 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Resmed Inc. Over the past six months, the relative strength of its shares against the market has been -6.16%. At the current price of $207.51, shares in Resmed Inc are trading at 4.71% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Resmed Inc PE ratio based on its reported earnings over the past 12 months is 41.78. The shares are currently trading at $207.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Resmed Inc's management team is headed by:
Here are the top five shareholders of Resmed Inc based on the size of their shareholding:
